失眠之營養介入

Nutritional Interventions for Insomnia

失眠是最常見的睡眠障礙，不僅損害生活品質，更與焦慮、憂鬱及心血管代謝疾病互為因果。由於大眾對失眠「症」的疾病認知不足，並顧慮安眠藥的副作用與依賴性，標榜天然無害的營養保健品遂成為熱門的替代選項。然而國際實證指引對失眠的營養介入普遍持保留態度。美國睡眠醫學會2017年指引明確不建議以褪黑激素、色胺酸或纈草治療失眠；2023年歐洲指引雖擴大檢視草藥與複方中藥，最終仍基於研究方法學的諸多缺陷未予建議。而確實市售產品多為複方而少有終端產品的直接驗證。即便有，相關研究受試者納入標準、介入成效評估偏重主觀量表，而缺乏客觀數據、樣本數與試驗期程不足，且副作用報告常被輕忽等等最常被提出。加上天然成分缺乏專利保障，研究經費投注受限，難以反覆驗證。故客觀而言，失眠營養介入並非無效，而是尚無強而有力的有效證據支持。然而驅使病人選擇治療方式的因素往往不止於療效，也並非完全基於客觀證據。過去研究顯示，補充及替代醫療的使用者多為中年、教育與收入較高族群，特別是重視整體與全人健康觀者，以及對「治本」的期待。作者近期完成的香蕉皮萃取物隨機對照試驗，即嘗試回應上述方法學挑戰，希望克服這些方法學上的缺失，提供實證。除科研因素外，法規限規範也是一個重要因素。最近由美國睡眠醫學會公告的指引，已將失眠認知行為介入與藥物的合併治療納入條件性建議，展現由藥物與非藥物「孰優孰劣」轉向「個人化整合」的趨勢。未來若能以更嚴謹的設計，結合生物標記與主客觀評估累積實證，並同步調整法規，失眠營養介入可望在臨床處置上佔有一席之地，以兼顧科學實證與病人的自主選擇與心理需求。

Among the most prevalent sleep disorders, insomnia compromise quality of life while maintaining bidirectional causal relationships with anxiety, depression, and cardiometabolic disease. Because public recognition of insomnia as a clinical disorder remains limited, and because concerns persist regarding the adverse effects and dependence liability of hypnotics, nutritional supplements marketed as natural and harmless have emerged as a popular alternative. International evidence-based guidelines, however, remain broadly reserved toward nutritional interventions for insomnia. The 2017 American Academy of Sleep Medicine guideline explicitly recommends against melatonin, tryptophan, and valerian for the treatment of insomnia. The 2023 European guideline, despite examining a wider range of herbal and compound traditional Chinese medicine preparations, likewise withheld recommendation on the basis of pervasive methodological shortcomings. Indeed, most commercially available products are multi-ingredient formulations that are seldom validated as end products. Even where trials exist, the most frequently cited limitations include imprecise inclusion criteria, outcome assessment weighted toward subjective questionnaires with a corresponding lack of objective data, insufficient sample sizes and trial durations, and the frequent under-reporting of adverse events. Because natural compounds also lack patent protection, research funding is constrained and replication is difficult to achieve. Objectively, therefore, nutritional interventions for insomnia cannot be deemed ineffective; rather, robust evidence of efficacy is not yet available.
Yet the factors driving patients' treatment choices extend beyond efficacy and are not wholly grounded in objective evidence. Prior research indicates that users of complementary and alternative medicine are predominantly middle-aged individuals of higher educational and income status, particularly those who endorse holistic conceptions of health and seek to address the root cause of their condition. The authors' recently completed randomized controlled trial of banana peel extract was designed to address the methodological deficiencies outlined above and to contribute more rigorous evidence. Beyond scientific considerations, the regulatory framework constitutes a further determinant. The most recent American Academy of Sleep Medicine guideline now includes combined cognitive behavioral therapy for insomnia and pharmacotherapy as a conditional recommendation, reflecting a shift from adjudicating the relative superiority of pharmacological versus non-pharmacological approaches toward personalized integration. If future work can accumulate evidence through more rigorous designs incorporating biomarkers alongside both subjective and objective assessment, with concurrent regulatory adaptation, nutritional interventions may secure a legitimate place in the clinical management of insomnia—one that honors both scientific evidence and patients' autonomous preferences and psychological needs.